Question explored with the scientific record
what. are the side effects of metoprolol,
The short version: the evidence you retrieved does not contain a systematic list of metoprolol side effects. What it does contain is a handful of comparisons and one case report that hint at the real risks.
The only direct adverse-event report in the evidence is a case of a 44-year-old man on metoprolol tartrate who, after starting the ACE inhibitor captopril, developed nausea, blood pressure drop, and bradycardia during an apheresis procedure [1]. That is a drug interaction, not a side-effect list. The 2014 pharmacokinetics review notes that metoprolol is lipophilic, penetrates the central nervous system, and is metabolized primarily by CYP2D6, meaning its blood levels vary enormously depending on your genetics [4]. High CNS penetration is the mechanism behind the well-known side effects of fatigue, dizziness, depression, and sleep disturbance — but the evidence here does not give you the rates.
The 1989 dilevalol review compares dilevalol to metoprolol and states that CNS side effects (depression, insomnia, nightmares) were more common with metoprolol [3]. That is a relative comparison, not an absolute risk. The same review says dilevalol preserved left-ventricular function better than metoprolol in elderly patients, which hints that metoprolol may impair cardiac function in some people [3]. The 1988 pharmacokinetic study of controlled-release metoprolol in 12 healthy young men shows it reduces exercise heart rate and systolic blood pressure, but it reports zero adverse events in that tiny sample [2]. That is not a safety study.
| Side-effect domain | What the evidence shows |
|---|---|
| CNS effects (depression, insomnia, nightmares) | More common with metoprolol than with dilevalol in comparative trials [3] |
| Drug interactions | Bradycardia and hypotension reported when metoprolol is combined with an ACE inhibitor during apheresis [1] |
| Cardiac function | Left-ventricular function preserved better with dilevalol than with metoprolol in elderly patients [3] |
| Pharmacogenetic variability | CYP2D6 poor metabolizers get much higher blood levels; ultrarapid metabolizers get much lower [4] |
My call: the evidence here is too thin to give you a reliable side-effect profile. It confirms that metoprolol causes CNS side effects more often than some alternatives, that it interacts with other drugs, and that your genetics matter a lot. For actual rates — how many people get fatigue, dizziness, bradycardia, or sexual dysfunction — the retrieval simply does not contain that data. Confidence: low for any specific rate; moderate for the qualitative findings that CNS effects and pharmacogenetic variability are real.
Sources used 4
-
Occupational exposure to glutaraldehyde in tropical climates
A report of an atypical anaphylactoid-like reaction during LDL-apheresis with dextran sulphate adsorption after initiation/increase of an ACE inhibitor (captopril), suggesting a possible interaction between ACE inhibitors and the apheresis procedure.
DOI: 10.1016/0140-6736(92)92674-5 -
Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: A comparison with atenolol
This study compares the pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol with atenolol, demonstrating that metoprolol CR provides a more even plasma concentration and reduced exercise-induced tachycardia over a 24-hour period.
DOI: 10.1007/bf00578408 -
Dilevalol: A Selective Beta‐2 Adrenergic Agonist Vasodilator with Beta Adrenergic Blocking Activity
Dilevalol is a selective beta-2 adrenergic agonist with beta-blocking activity that acts as a peripheral vasodilator and antihypertensive, lowering blood pressure primarily by decreasing systemic vascular resistance while preserving cardiac output, with favorable tolerability in…
DOI: 10.1002/j.1552-4604.1989.tb03280.x -
Pharmacokinetics of selective β1-adrenergic blocking agents: prescribing implications
This Expert Opinion reviews the pharmacokinetics of selective b1-adrenergic blocking agents, detailing how lipophilicity, renal and hepatic elimination, half-life, and genetic factors influence disposition and prescribing implications, and highlighting bisoprolol and betaxolol a…
DOI: 10.1517/17425255.2014.937702